|Bid||3.1600 x 1800|
|Ask||3.1700 x 1300|
|Day's range||3.1000 - 3.2400|
|52-week range||2.8700 - 8.5800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||08 May 2023 - 12 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.80|
Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SOMERVILLE, Mass., March 29, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates.